osimertinib + savolitinib

Osimertinib + savolitinib is a combination therapy of two oral small-molecule tyrosine kinase inhibitors used primarily in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations and MET amplification or overexpression. Osimertinib is a third-generation, irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, including both sensitizing and T790M resistance mutations. Savolitinib is a potent and highly selective inhibitor of the MET receptor tyrosine kinase. The combination targets both EGFR and MET pathways to overcome acquired resistance to EGFR inhibitors mediated by MET amplification, providing improved antitumor activity compared to monotherapy. This regimen has shown promising efficacy in clinical trials for patients who have progressed on prior EGFR-TKI therapy due to MET-driven resistance[1][2][5][6][8].

Brand names

OrpathysTagrisso

Other names

savolitinib + osimertinib